TR201908367T4 - Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi - Google Patents

Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi Download PDF

Info

Publication number
TR201908367T4
TR201908367T4 TR2019/08367T TR201908367T TR201908367T4 TR 201908367 T4 TR201908367 T4 TR 201908367T4 TR 2019/08367 T TR2019/08367 T TR 2019/08367T TR 201908367 T TR201908367 T TR 201908367T TR 201908367 T4 TR201908367 T4 TR 201908367T4
Authority
TR
Turkey
Prior art keywords
antibody
agent
antibodies
endogsycosids
therapeutic use
Prior art date
Application number
TR2019/08367T
Other languages
English (en)
Inventor
David Max Crispin Matthew
Neil Scanlan Christopher
Original Assignee
Immago Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immago Biosystems Ltd filed Critical Immago Biosystems Ltd
Publication of TR201908367T4 publication Critical patent/TR201908367T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bir hastalığın bir tedavi yönteminde kullanılması için endojen serum antikorlarının enzimatik degradasyonu ile Fc reseptör bağlanımını azaltan bir ajan olup, özelliği; ajanın bir endoglikosidaz, bir proteaz ya da bir protein-N-glikanaz olmasıdır ve bir antikorun terapötik potensini arttıran bir yöntem olup, özelliği; bahsi geçen antikorun etki şeklinin, Fc: FcR etkileşimine dayanmasıdır ve özelliği; yöntemin aşağıdaki adımları kapsamasıdır: (a) bahsi geçen ajanın bir deneğe tatbik edilmesi; ve akabinde, (b) belirlenen bir zaman aralığı sonrasında, bahsi geçen antikorun deneğe tatbik edilmesi.
TR2019/08367T 2012-01-26 2013-01-25 Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi TR201908367T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201201314A GB201201314D0 (en) 2012-01-26 2012-01-26 Composition

Publications (1)

Publication Number Publication Date
TR201908367T4 true TR201908367T4 (tr) 2019-06-21

Family

ID=45840985

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08367T TR201908367T4 (tr) 2012-01-26 2013-01-25 Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi

Country Status (17)

Country Link
US (4) US20150125443A1 (tr)
EP (1) EP2806892B1 (tr)
JP (1) JP6249962B2 (tr)
CN (2) CN108619509A (tr)
CY (1) CY1122060T1 (tr)
DK (1) DK2806892T3 (tr)
ES (1) ES2728290T3 (tr)
GB (1) GB201201314D0 (tr)
HR (1) HRP20191022T1 (tr)
HU (1) HUE044632T2 (tr)
IN (1) IN2014DN06722A (tr)
LT (1) LT2806892T (tr)
PL (1) PL2806892T3 (tr)
PT (1) PT2806892T (tr)
SI (1) SI2806892T1 (tr)
TR (1) TR201908367T4 (tr)
WO (1) WO2013110946A1 (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
GB201318490D0 (en) * 2013-10-18 2013-12-04 Genovis Ab Method
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN108026518B (zh) * 2015-07-16 2022-09-06 第一三共株式会社 新型endos突变型酶
CN108495653A (zh) * 2016-01-27 2018-09-04 免疫医疗有限责任公司 用于制备具有定义的糖基化模式抗体的方法
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP2017226648A (ja) * 2016-06-17 2017-12-28 ＳｏｎｏＣｏｒｅ株式会社 分子標的薬バブルおよび分子標的薬バブルの製造方法
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN110151987B (zh) * 2018-02-11 2023-10-13 汕头大学医学院 对称IgG及其组合物在制备治疗及预防肿瘤的药物中的用途
CN115023422A (zh) * 2019-12-12 2022-09-06 德国费森尤斯卡比有限公司 糖基化多肽
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
EP4162951A4 (en) * 2020-06-05 2024-07-10 Shanghai Bao Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND ASSOCIATED APPLICATION
CN113769058B (zh) * 2020-06-10 2024-09-06 上海宝济药业股份有限公司 一种药物组合及其应用
CN120078887A (zh) * 2020-09-21 2025-06-03 上海宝济药业股份有限公司 一种药物组合及其应用
JP7820734B2 (ja) * 2020-12-11 2026-02-26 東ソー株式会社 免疫グロブリン結合糖鎖の予測方法
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040136986A1 (en) 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CN1665934B (zh) 2002-03-19 2010-05-26 国际植物研究所 GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达
WO2004007499A1 (en) 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
DK2190984T3 (da) * 2007-09-14 2013-12-02 Genovis Ab Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG
JP7093612B2 (ja) * 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法

Also Published As

Publication number Publication date
PL2806892T3 (pl) 2019-09-30
CN108619509A (zh) 2018-10-09
JP6249962B2 (ja) 2017-12-20
US20170274070A1 (en) 2017-09-28
HUE044632T2 (hu) 2019-11-28
US20150125443A1 (en) 2015-05-07
CY1122060T1 (el) 2020-11-25
SI2806892T1 (sl) 2019-08-30
CN104519911B (zh) 2018-07-17
EP2806892A1 (en) 2014-12-03
US20200345844A1 (en) 2020-11-05
WO2013110946A1 (en) 2013-08-01
JP2015511223A (ja) 2015-04-16
DK2806892T3 (da) 2019-06-11
HRP20191022T1 (hr) 2019-09-06
EP2806892B1 (en) 2019-03-06
IN2014DN06722A (tr) 2015-05-22
LT2806892T (lt) 2019-07-25
ES2728290T3 (es) 2019-10-23
US20230398212A1 (en) 2023-12-14
GB201201314D0 (en) 2012-03-07
CN104519911A (zh) 2015-04-15
PT2806892T (pt) 2019-06-17

Similar Documents

Publication Publication Date Title
TR201908367T4 (tr) Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi
EA201290590A1 (ru) Модифицированные туберкулезные антигены
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201391564A1 (ru) Полипептиды антитела, которые антагонизируют cd40
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EA201491006A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
EA201300239A1 (ru) Антитела к fap и способы их применения
NI201700001A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
BR112015000657A8 (pt) uso de uma célula geneticamente modificada para expressar um car.
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
TN2015000050A1 (en) Methods of treating a tauopathy
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
TR201819812T4 (tr) Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
TN2014000120A1 (en) Cd27l antigen binding proteins
EA201400579A1 (ru) Антитела к il-36r
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201391585A1 (ru) Терапевтические нуклеазные композиции и способы
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2013011385A (es) Moleculas de union a cd37 y sus inmunoconjugados.
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17